An Act to Amend Maine's Prescription Drug Labeling Law by Allowing the Removal of the Name of a Prescriber of Mifepristone, Misoprostol and Their Generic Alternatives
Summary
LD 538 amends Maine’s prescription drug labeling law to create a narrow exception for mifepristone, misoprostol, and their generic alternatives. Under current law, prescription labels generally must include the name of the practitioner prescribing the drug. This bill allows, at the prescribing practitioner’s request, the label for those specific medications to list the name of the health care facility associated with the practitioner instead of the practitioner’s personal name.
The bill does not change the general labeling requirements for other prescription drugs. It leaves in place the existing requirements for prescription number, fill date, patient name, directions, drug name and strength, beyond-use date, and pharmacy information, while carving out a limited alternative labeling option for these medications. The measure was enacted as Public Law 2025, chapter 142.
Impact
The bill amends 32 MRSA §13794, Maine’s prescription drug labeling statute, by adding a specific exception for mifepristone, misoprostol, and their generic alternatives. For those drugs, the label may identify the health care facility instead of the individual prescriber if the prescriber requests it. This change affects pharmacies, prescribers, and patients receiving these medications, but only in this narrow context; it does not broadly alter labeling rules for other prescriptions or the underlying dispensing requirements.
Sentiment
The voting history suggests the bill was supported, but not unanimously, indicating some division. The House accepted the majority ought-to-pass as amended report by a close 75-71 vote, and the Senate followed with a 19-13 vote. The final enactment as public law shows the measure ultimately had enough support to pass, but the margins indicate it was a contested issue rather than a consensus bill.
Contention
The likely point of contention was the bill’s focus on mifepristone and misoprostol, medications associated with abortion care and reproductive health. Supporters appear to have favored allowing facility names to appear instead of individual prescriber names, likely to reduce personal identification of clinicians. Opponents likely objected either to the special treatment for these medications or to the broader policy implications of shielding prescriber identity. The narrow vote margins in both chambers reflect that this privacy-related change was politically sensitive.